List of Olumiant drug patents

Olumiant is owned by Eli Lilly And Co.

Olumiant contains Baricitinib.

Olumiant has a total of 5 drug patents out of which 0 drug patents have expired.

Olumiant was authorised for market use on 31 May, 2018.

Olumiant is available in tablet;oral dosage forms.

Olumiant can be used as treatment of rheumatoid arthritis, treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo), treatment of adult patients with severe alopecia areata.

Drug patent challenges can be filed against Olumiant from May, 2022.

The generics of Olumiant are possible to be released after 29 March, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8158616 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Mar, 2029

(6 years from now)

US9089574 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
Nov, 2032

(9 years from now)

US11045474 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections
Nov, 2032

(9 years from now)

US9737469 ELI LILLY AND CO Methods for treating hair loss disorders
Mar, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) May 10, 2025
New Chemical Entity Exclusivity (NCE) May 31, 2023

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of rheumatoid arthritis; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo); Treatment of adult patients with severe alopecia areata

Dosage: TABLET;ORAL

How can I launch a generic of OLUMIANT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in